Overview

• A peer‑reviewed study published Oct. 6 in Signal Transduction and Targeted Therapy reports bioactive “supramolecular” nanoparticles that restored blood–brain barrier transport and reduced Alzheimer’s pathology in mouse models.
• Engineered mice receiving three injections showed a rapid 50–60% drop in brain amyloid‑β within one hour of dosing.
• The nanoparticles are designed to mimic ligands of the LRP1 receptor, reactivating receptor‑mediated transport to move toxic proteins out of the brain.
• Behavior and memory improved for months after treatment, including an 18‑month‑old mouse that returned to normal behavior six months post‑therapy.
• The work, led by IBEC and West China Hospital with UCL collaborators, has prompted calls for replication, detailed safety and toxicology studies, and early‑phase human trials from researchers and Alzheimer’s groups.